日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities

癌症基因组不稳定性的代谢驱动因素:机制和治疗机遇

Wang, Yu-Shun; Qian, Li-Heng; Liu, Cui-Cui; Yu, Ke-Da

CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer

CD8 靶向免疫化疗可提高高肿瘤负荷三阴性乳腺癌的病理完全缓解率

Chen, Li; Jiang, Shu-Hao; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Di, Gen-Hong; Zhang, Wen-Juan; Ma, Lin-Xiaoxi; Liang, Qian-Nan; Shen, Yu; Wang, Zhong-Hua; Shao, Zhi-Ming; Li, Jun-Jie

Electron localization in noncompact covalent bonds captured by the r(2)SCAN+V approach

利用 r(2)SCAN+V 方法捕捉非紧密共价键中的电子局域化

Zhang, Yubo; Ke, Da; Maniar, Rohan; Lebeda, Timo; Zhang, Peihong; Sun, Jianwei; Perdew, John P

Application of nanoparticles in the therapeutic management of endometrial cancer

纳米颗粒在子宫内膜癌治疗中的应用

Ke, Da; Li, Wenzhe; Chen, Qian; Luo, Liang; Wang, Ya; Meng, Fanling; Sun, Yaling

Logarithmically transformed lactate-to-hemoglobin ratio demonstrates a threshold effect on 28-day mortality in sepsis: Analysis of the MIMIC-IV database

对数转换后的乳酸/血红蛋白比值对脓毒症患者28天死亡率存在阈值效应:MIMIC-IV数据库分析

Chen, Huang; Ke, Da; Zheng, Xiuqin; Song, Haiyang; Lin, Shirong

Breast cancer: pathogenesis and treatments

乳腺癌:发病机制和治疗

Xiong, Xin; Zheng, Le-Wei; Ding, Yu; Chen, Yu-Fei; Cai, Yu-Wen; Wang, Lei-Ping; Huang, Liang; Liu, Cui-Cui; Shao, Zhi-Ming; Yu, Ke-Da

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

卡铂强化辅助化疗与标准化疗对高危早期三阴性乳腺癌女性患者生存率的影响(CITRINE):一项随机、开放标签的3期临床试验

Liu, Yin; Gong, Yue; Zhu, Xiu-Zhi; Liu, Guang-Yu; Yu, Ke-Da; Yang, Fan; Chen, Li; He, Min; Hu, Zhen; Chen, Can-Ming; Cao, A-Yong; Li, Jun-Jie; Hou, Yi-Feng; Di, Gen-Hong; Wu, Jiong; Jiang, Yi-Zhou; Fan, Lei; Wang, Zhong-Hua; Shao, Zhi-Ming

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)

Sitravatinib 联合 tislelizumab 治疗局部复发或转移性三阴性乳腺癌:一项多队列、单臂 II 期临床试验(SPARK 试验)

Liu, Xi-Yu; Sui, Xin-Yi; Xu, Ying; Yang, Fan; Wu, Song-Yang; Zhu, Xiu-Zhi; Zuo, Ke; Cao, Shuo-Wen; Jin, Xi; Chen, Li; Ma, Lin-Xiaoxi; Zhang, Wen-Juan; Ye, Fu-Gui; Qu, Fei-Lin; Ma, Ding; Xiao, Yi; Di, Gen-Hong; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Hu, Xin; Jiang, Yi-Zhou; Wang, Zhong-Hua; Shao, Zhi-Ming; Fan, Lei

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study

一项基于化疗敏感性的前瞻性 II 期新辅助治疗研究——FINEST 研究(HR+/HER2- 乳腺癌)。

Chen, Li; Wu, Wen-Ya; Liang, Fei; Liu, Guang-Yu; Yu, Ke-Da; Wu, Jiong; Di, Gen-Hong; Fan, Lei; Wang, Zhong-Hua; Li, Jun-Jie; Shao, Zhi-Ming

Size-dependent translocation of polystyrene nanoplastics across biological barriers in mammals

聚苯乙烯纳米塑料在哺乳动物体内跨越生物屏障的尺寸依赖性转运

Zhang, Hong-Jie; Li, Sicheng; Wang, Xin-Lei; Zhang, Ke-Da; Fang, Hai-Tao; Wu, Xuan; Huang, Ziyun; Jiang, Wei; Yang, Liuyan; Tan, Qiao-Guo; Pan, Bingcai; Ji, Rong; Wang, Ping; Xing, Baoshan; Miao, Ai-Jun